Area of research
Oncology · Epidemiology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Microscopic Colitis, Colorectal Cancer Treatments and Studies, and Inflammatory Bowel Disease.
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Genetic polymorphism of IDOL gene was associated with the susceptibility of coronary artery disease in Han population in Xinjiang, China
Serological Thymidine Kinase1 is a Biomarker for Early Risk of Tumours Progression —Real World Data from a Health Screening Study on a Cohort of 35,365 People
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
IDOL gene variant is associated with hyperlipidemia in Han population in Xinjiang, China
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson